BIOLOGICAL · Unmapped registry intervention
Interferon beta-1a
Find medicine records ·
Find other trials using this name
Clinical trial
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
NCT00050778
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
BIOLOGICAL · Unmapped registry intervention
Alemtuzumab 12 mg
Find medicine records ·
Find other trials using this name
BIOLOGICAL · Unmapped registry intervention
Alemtuzumab 24 mg
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Multiple Sclerosis, Relapsing-Remittingunresolved
Interventions
Sponsors & collaborators
Genzyme, a Sanofi Companylead sponsor
Bayercollaborator
Mapped research locations
MoscowRussia4ZagrebCroatia3San AntonioTexas, United States2WarsawPoland2Saint PetersburgRussia2HoustonTexas, United States1BaltimoreMaryland, United States1TampaFlorida, United States1OrlandoFlorida, United States1DenverColorado, United States1DetroitMichigan, United States1Las VegasNevada, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00050778 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.